Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.83 +0.06 (+0.23%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,242,128
Open 25.76
Bid (Size) 25.81 (9)
Ask (Size) 25.82 (17)
Prev. Close 25.77
Today's Range 25.70 - 25.95
52wk Range 24.48 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 6.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Pfizer Stock in Trouble?
Via The Motley Fool
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success. 
Via MarketBeat
Topics Government Intellectual Property
Exposures Intellectual Property Political Product Safety

Performance

YTD
-13.12%
-13.12%
1 Month
-9.24%
-9.24%
3 Month
-10.06%
-10.06%
6 Month
-8.40%
-8.40%
1 Year
-14.13%
-14.13%

More News

Read More
Billionaires Are Buying Up Beaten-Down Pfizer Stock. Should You Follow Their Lead?
Via The Motley Fool
Advocating for Justice: Supporting Individuals in the Depo-Provera Litigation
Via Get News
Topics Lawsuit
Exposures Financial Legal
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
Via Benzinga
(PFE) - Analyzing Pfizer's Short Interest
Via Benzinga
Pfizer Unusual Options Activity For November 20
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?
Via The Motley Fool
Topics Stocks
Exposures US Equities
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Via The Motley Fool
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
Via Investor's Business Daily
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Via Benzinga
Exposures Product Safety
3 Dividend Stocks That Are Screaming Buys in November
Via The Motley Fool
Is It Time to Sell Eli Lilly and Pfizer Stocks?
Via The Motley Fool
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nomination
Via Benzinga
Topics Government
Exposures Political
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Via The Motley Fool
Is Biotech’s Bull Run Over? Examining Election Impacts
Via MarketBeat
Topics ETFs Government
Exposures Political
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Via The Motley Fool
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
Via Benzinga
Pfizer Announces New Chief Scientific Officer and President, Research & Development
From Pfizer Inc.
Via Business Wire
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Via Benzinga
2 High-Yield Dividend Stocks I Can't Stop Buying
Via The Motley Fool
Not-So-Big Pharma
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.